View profile

FarmaKology Newsletter - Issue #16

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


July 30 · Issue #16 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “”, and happy to have you featured on our newsletter!

Today's Startup
Bridge Therapeutics Inc.
Bridge Therapeutics®, based in Birmingham, is an innovative development-stage specialty pharmaceutical company pursuing U.S. (FDA) and (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. Bridge Therapeutics'​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory.
Novartis today announced topline results from the global Phase III PARAGON-HF study, investigating the safety and efficacy of sacubitril/valsartan versus the active comparator valsartan in HFpEF patients. The trial narrowly missed statistical significance for its composite primary endpoint of reducing cardiovascular death and total heart failure hospitalizations. Safety and tolerability were consistent with previously reported sacubitril/valsartan data.
Pfizer is spinning off its off-patent and generics business UpJohn, and combining it with generic drugmaker Mylan to create a giant off-patent group with global annual revenues worth about $20 billion.
Indian pharma firms are seeking partners that can make tangible business contributions, safeguard IP, ensure operational control and manage talent .Dr Reddy’s, Aurobindo Pharma, Cipla, Sun Pharmaceuticals Industries are looking at China as a big opportunity.
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
Research & Study
SIPN - the next generation PBM - PPN Episode 819 by Pharmacy Podcast Network | Free Listening on SoundCloud
Job Opportunities
The Consequences of Not Getting Vaccinated
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue